<DOC>
	<DOC>NCT00771823</DOC>
	<brief_summary>A placebo controlled study of the impact on insulin sensitivity and lipid profile of maraviroc 300 mg twice daily in HIV negative male volunteers.</brief_summary>
	<brief_title>Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects must have documented negative HIV serology by ELISA and P24 antigen Subjects must be clinically well males aged between 18 to 60 years. Fasting blood glucose, total cholesterol and triglycerides within normal limits Hepatic transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN) Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm3; platelets ≥ 50,000/mm3; hemoglobin ≥ 8.0 g/dL) Serum amylase ≤ 1.5 × ULN Sexually active males must use condoms during the course of the study Life expectancy ≥ 1 year Willing and able to provide informed consent Subjects with a waist hip ratio &gt; 0.97 or BMI &gt; 28 kg/m2 will be excluded Acute or chronic hepatitis B infection (determined by positive hepatitis B surface antigen result at the screening visit) Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody result at the screening visit) Other metabolic syndrome or disease process in the opinion of the investigator likely to cause marked disturbance in glucose and lipid homeostasis including hypertension. Receiving ongoing therapy with any of the following: Metabolically active medications Any lipidlowering medication Hormonal agents (oestrogens or androgens) Glucocorticoids Betablockers Thiazide diuretics Thyroid preparations Psychotropic agents Anabolic steroids Megestrol acetate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>